OrbiMed Capital GP VIII LLC — SEC Form 4 filings
SEC reporting owner CIK 1845804. 23 Form 4 filings on record with FilingPulse; latest filed 2026-08-12.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2024-01-31 to 2026-08-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 11 legs across 7 filings — 4,125,507 shares, $60,923,223 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 47 legs across 13 filings — 1,605,551 shares, $75,782,702 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 46.
- Largest priced transaction: purchase of 1,000,000 shares @ $15.00 ($15,000,000) in Scribe Therapeutics, Inc., filed 2026-07-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | Director | 11 | 1 leg · 550,000 sh · $9,900,000 | 20 legs · 1,235,000 sh · $55,674,636 | 3 |
| Disc Medicine, Inc. (IRON) | Director | 4 | 3 legs · 83,334 sh · $3,000,024 | 27 legs · 370,551 sh · $20,108,066 | — |
| Scribe Therapeutics, Inc. (SCTX) | Director | 1 | 1 leg · 1,000,000 sh · $15,000,000 | — | 2 |
| Upstream Bio, Inc. (UPB) | Director, 10% owner | 1 | 2 legs · 825,000 sh · $14,025,000 | — | 6 |
| BlossomHill Therapeutics, Inc. (BLSM) | Director | 1 | 1 leg · 625,000 sh · $10,000,000 | — | 4 |
| ArriVent Biopharma, Inc. (AVBP) | Director, 10% owner | 1 | 2 legs · 444,444 sh · $7,999,992 | — | 8 |
| Traws Pharma, Inc. (TRAW) | 10% owner | 2 | 1 leg · 597,729 sh · $998,207 | — | 5 |
| Lomond Therapeutics Holdings, Inc. | Director | 1 | — | — | 13 |
| Kinnate Biopharma Inc. (KNTE) | Director, 10% owner | 1 | — | — | 5 |
Form 4 filings — OrbiMed Capital GP VIII LLC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-12 | 4 | BlossomHill Therapeutics, Inc. (BLSM) jointly with ORBIMED ADVISORS LLC | Conversion (C): 1,039,996 · Conversion (C): 1,049,283 · Purchase (P): 625,000 @ $16 · Conversion (C): 1,039,996 (derivative) @ $0 · Conversion (C): 1,049,283 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | Scribe Therapeutics, Inc. (SCTX) jointly with ORBIMED ADVISORS LLC | Conversion (C): 348,825 · Purchase (P): 1,000,000 @ $15 · Conversion (C): 2,065,672 (derivative) @ $0 | EDGAR |
| 2026-07-09 | 4 | Sionna Therapeutics, Inc. (SION) jointly with ORBIMED ADVISORS LLC | Sale (S): 85,918 @ $44.86 | EDGAR |
| 2026-07-02 | 4 | Sionna Therapeutics, Inc. (SION) jointly with ORBIMED ADVISORS LLC | Sale (S): 115,844 @ $45.50 | EDGAR |
| 2026-05-29 | 4 | Sionna Therapeutics, Inc. (SION) jointly with ORBIMED ADVISORS LLC | Sale (S): 101 @ $44.49 | EDGAR |
| 2026-05-11 | 4 | Sionna Therapeutics, Inc. (SION) jointly with ORBIMED ADVISORS LLC | Sale (S): 48,546 @ $44.61 · Sale (S): 59,767 @ $44.58 · Sale (S): 184,639 @ $46.22 | EDGAR |
| 2026-04-28 | 4 | Traws Pharma, Inc. (TRAW) jointly with ORBIMED ADVISORS LLC | Purchase (P): 597,729 @ $1.67 · Purchase (P): 597,729 (derivative) · Purchase (P): 597,729 (derivative) · Purchase (P): 1,793,187 (derivative) | EDGAR |
| 2026-04-21 | 4 | Sionna Therapeutics, Inc. (SION) jointly with ORBIMED ADVISORS LLC | Sale (S): 52,397 @ $44.68 · Sale (S): 2,948 @ $44.52 | EDGAR |
| 2026-04-16 | 4 | Sionna Therapeutics, Inc. (SION) jointly with ORBIMED ADVISORS LLC | Sale (S): 47,814 @ $44.51 · Sale (S): 235,863 @ $44.64 · Sale (S): 226,906 @ $45.34 | EDGAR |
| 2026-02-04 | 4 | Sionna Therapeutics, Inc. (SION) jointly with ORBIMED ADVISORS LLC | Sale (S): 1,890 @ $44.57 · Sale (S): 29,063 @ $44.58 | EDGAR |
| 2025-12-29 | 4 | Sionna Therapeutics, Inc. (SION) jointly with ORBIMED ADVISORS LLC | Sale (S): 33,356 @ $44.55 | EDGAR |
| 2025-12-19 | 4 | Sionna Therapeutics, Inc. (SION) jointly with ORBIMED ADVISORS LLC | Sale (S): 900 @ $44.50 · Sale (S): 100 @ $44.49 · Sale (S): 875 @ $44.49 | EDGAR |
| 2025-11-26 | 4 | Sionna Therapeutics, Inc. (SION) jointly with ORBIMED ADVISORS LLC | Sale (S): 94,583 @ $44.54 · Sale (S): 11,890 @ $44.60 · Sale (S): 1,600 @ $44.49 | EDGAR |
| 2025-03-26 | 4 | Disc Medicine, Inc. (IRON) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC | Sale (S): 1,956 @ $54.11 · Sale (S): 3,026 @ $54.11 · Sale (S): 756 @ $54.11 | EDGAR |
| 2025-03-21 | 4 | Disc Medicine, Inc. (IRON) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC | Sale (S): 13,517 @ $54.02 · Sale (S): 20,911 @ $54.02 · Sale (S): 5,228 @ $54.02 · Sale (S): 941 @ $54.01 · Sale (S): 1,457 @ $54.01 · Sale (S): 364 @ $54.01 · +3 more | EDGAR |
| 2025-03-12 | 4 | Disc Medicine, Inc. (IRON) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC | Sale (S): 68,766 @ $54.29 · Sale (S): 106,384 @ $54.29 · Sale (S): 26,596 @ $54.29 · Sale (S): 136 @ $55.01 · Sale (S): 211 @ $55.01 · Sale (S): 53 @ $55.01 · +9 more | EDGAR |
| 2025-02-10 | 4 | Sionna Therapeutics, Inc. (SION) jointly with ORBIMED ADVISORS LLC | Conversion (C): 3,154,959 · Purchase (P): 550,000 @ $18 · Conversion (C): 2,560,951 (derivative) @ $0 · Conversion (C): 2,048,760 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Traws Pharma, Inc. (TRAW) jointly with ORBIMED ADVISORS LLC | Purchase (P): 96,348 (derivative) · Purchase (P): 96,348 (derivative) | EDGAR |
| 2024-11-05 | 4 | Lomond Therapeutics Holdings, Inc. jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Capital GP IX LLC | Conversion (C): 323,916 @ $3.20 · Conversion (C): 215,146 @ $3.20 · Conversion (C): 389,078 @ $3.60 · Conversion (C): 230,753 @ $3.60 · Conversion (C): 74,613 @ $3.60 · Grant/award (A): 808,894 @ $4 · +7 more | EDGAR |
| 2024-10-17 | 4 | Upstream Bio, Inc. (UPB) jointly with ORBIMED ADVISORS LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P. | Conversion (C): 721,956 · Purchase (P): 165,000 @ $17 · Conversion (C): 2,887,833 · Purchase (P): 660,000 @ $17 · Conversion (C): 524,500 (derivative) · Conversion (C): 2,098,000 (derivative) · +2 more | EDGAR |
| 2024-06-20 | 4 | Disc Medicine, Inc. (IRON) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC | Purchase (P): 28,404 @ $36 · Purchase (P): 43,944 @ $36 · Purchase (P): 10,986 @ $36 | EDGAR |
| 2024-04-05 | 4 | Kinnate Biopharma Inc. (KNTE) jointly with ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Asia GP IV, L.P., OrbiMed Advisors IV Ltd, OrbiMed Genesis GP LLC, ORBIMED CAPITAL LLC | Disposition to issuer (D): 1,368,339 · Disposition to issuer (D): 4,738,453 · Disposition to issuer (D): 1,368,338 · Disposition to issuer (D): 84,599 · Disposition to issuer (D): 450,000 | EDGAR |
| 2024-01-31 | 4 | ArriVent Biopharma, Inc. (AVBP) jointly with ORBIMED ADVISORS LLC, OrbiMed Advisors IV Ltd, OrbiMed Asia GP IV, L.P. | Conversion (C): 821,827 · Conversion (C): 821,827 · Conversion (C): 469,615 · Conversion (C): 469,615 · Purchase (P): 222,222 @ $18 · Purchase (P): 222,222 @ $18 · +4 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1845804 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →